New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates. In this episode, experts examine combination ...

Nerandomilast (PDE4B inhibitor) joined nintedanib and pirfenidone as FDA-approved options, with each demonstrating reduced FVC decline rates in IPF. Clinical benefit is clearest in progressive ...

Pelabresib plus Jakafi significantly reduced spleen volume and improved symptoms in myelofibrosis patients compared to Jakafi alone, with sustained benefits at 96 weeks. The combination therapy showed ...

Congruence between circulating tumor DNA and radiographic response during treatment of advanced sarcoma patients. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

(a) Schematic of IHoM and IHeM models. NC: neutral cells; AC: cells carrying antigen mutations; IC: immune-recognizable cells; EC: immune-escaped cells. (b) Response of IHoM and IHeM to monotherapies ...

In the decade since palbociclib (Ibrance) received FDA approval, results from multiple clinical trials have provided a strong evidence base to make cyclin-dependent kinase (CDK)4/6 inhibitors, in ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of inhibitor ...

Aug 13, 2025, 12:15 PM ETAllurion Technologies Inc. (ALUR) Stock, ALURW StockAI-Generated Earnings Calls Insights ...

Drug combination screening is transforming treatment development by focusing on how multiple drugs can work together—rather than relying on a single therapy. This approach allows researchers to ...